Navigation Links
Effectively Bringing Fixed Dose Combination Products to Market to Maintain Growth and Pipelines
Date:3/8/2013

CHAPEL HILL, N.C., March 8, 2013 /PRNewswire/ -- The pharmaceutical industry has turned to sustainable growth opportunities to address the pipeline and patent challenges facing many organizations in the sector. One opportunity for growth lies in extending a product's patent life by combining branded products.

Fixed dose combination (FDC) products have clinical and commercial advantages. For the drug manufacturer, an FDC product can extend the therapeutic advantage and becomes part of lifecycle management. For the patient, FDC products can address unmet medical needs and reduce pill burdens.

But there is more to success than just developing a new FDC and launching it. Successful research and development leaders recognize that understanding the market and audience will smooth the FDC launch process, according to a study by benchmarking leader Best Practices, LLC.

"Fixed Dose Combination Products: Successful Strategies for Developing and Bringing FDC Products to Market" identifies successful strategies and innovative practices for developing and bringing FDC products to market. Through executive insights and advice, the study also addresses the pitfalls and obstacles to avoid in this work.

A third of the FDC leaders who participated in the study said the most important lesson learned from their work with FDC products is the need to focus on the differentiated benefit and value that the product can bring to patients, physicians and payers.

Some of the issues addressed in this research include:

  • Chief reason for pursuing FDC development
  • Measures used to evaluate success
  • Years from decision to develop through launch
  • Cost of FDC product development
  • Time lapsed from initial contact to signed contractual agreement with
    '/>"/>

SOURCE Best Practices, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Ensuring Pharmaceutical Organizations are Effectively Organizing and Deploying Medical Science Liaisons across Diverse Customer Groups
2. Louisiana Pain Specialist Dr. Arnold Feldman Uses Advanced Techniques to Effectively Treat Herniated Disc
3. Effectively Using Communication Channels and Tools to Reach Core Decision Makers in Organizations Across all Business Sectors
4. Positioning Strategies Effectively Minimize Cannibalization of a Legacy Brand When Expanding a Product Portfolio
5. Nutrastar International Completes Multi-Year Production Expansion Project Bringing Cordyceps Capacity to 100 Tons
6. For Drug Manufacturers Bringing a New Product to Market, Gaining the Support of Influential Doctors Is a Mission-Critical Priority
7. Clinical Site Services Is Bringing 3x More Patient Enrollment to the 48th Annual DIA Meeting
8. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
9. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
10. American Journal of Medicine Publishes Hypertension Study Comparing the Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone versus Azilsartan Medoxomil Co-administered with Hydrochlorothiazide
11. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... , July 7, 2015   Decision Resources ... differences in dialysis patient management in the U.S. ... submitted by U.S. and EU5 nephrologists from approximately ... binders are the most commonly used renal medications ... iron differs considerably between the two regions.      ...
(Date:7/7/2015)...   InspireMD, Inc. (NYSE MKT: NSPR) ... protection systems ("EPS"), today announced that its MGuard ... MicroNet ™ has received the Frost & ... Award.  Through active market research efforts, Frost & ... the successful introduction of new and innovative products, ...
(Date:7/7/2015)... 2015 Oasmia Pharmaceutical AB, ... within human and veterinary oncology, today announced that ... the United States , designed to ... animal therapeutic.      (Logo: http://photos.prnewswire.com/prnh/20150420/740096) , ... , Paccal Vet-CA1 was previously distributed ...
Breaking Medicine Technology:Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 2Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 3InspireMD Receives Frost & Sullivan 2015 European Coronary Stent New Product Innovation Award 2InspireMD Receives Frost & Sullivan 2015 European Coronary Stent New Product Innovation Award 3InspireMD Receives Frost & Sullivan 2015 European Coronary Stent New Product Innovation Award 4InspireMD Receives Frost & Sullivan 2015 European Coronary Stent New Product Innovation Award 5Oasmia Pharmaceutical Launches US Brand and Sales Platform 2
... April 29, 2011 Centocor Ortho Biotech Products, L.P., ... Drug Application (NDA) for trabectedin for the treatment of ... based on the U.S. Food and Drug Administration,s (FDA) ... to obtain approval. The NDA was submitted ...
... Phil Hagerman, president and CEO of Diplomat Specialty Pharmacy ... of the Year. The award was announced at ... annual award along with Grant Thornton LLP, WWJ Newsradio 950 ... Hagerman was chosen from among 45 nominees profiled during the ...
Cached Medicine Technology:Centocor Ortho Biotech Products, L.P. Voluntarily Withdraws NDA for Trabectedin 2Diplomat Specialty Pharmacy's Hagerman Named Grant Thornton Leader & Innovator of the Year 2Diplomat Specialty Pharmacy's Hagerman Named Grant Thornton Leader & Innovator of the Year 3
(Date:7/7/2015)... Aspen, CO (PRWEB) , ... July 07, 2015 ... ... 726 skin cancer screenings at the Aspen Ideas Festival (AIF), identifying 18 possible ... These potential diagnoses must be confirmed with additional testing. , The Aspen Ideas ...
(Date:7/7/2015)... ... July 07, 2015 , ... A June 29th ... that have emerged about Hillary Clinton. Two plastic surgeons consulted by the publication ... than she has in some time and speculate that she might have benefited ...
(Date:7/7/2015)... ... July 07, 2015 , ... Celestix Networks, ... VE and CelestixFederated VA Series virtual appliances. These virtual platforms expand the ... products, which have proven to simplify the on-premises deployment of unified remote access ...
(Date:7/7/2015)... N.J. (PRWEB) , ... July ... ... CTLT), the leading global provider of advanced delivery technologies and development solutions ... signed an exclusive licensing agreement with Excelimmune, Inc. to access its antibody ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... enhance the experience for its patient community using its IDF ePHR, an electronic ... with primary immunodeficiency diseases (PI) to easily track their health information, including symptoms, ...
Breaking Medicine News(10 mins):Health News:More than 700 Screened for Skin Cancer at 2015 Aspen Ideas Festival 2Health News:More than 700 Screened for Skin Cancer at 2015 Aspen Ideas Festival 3Health News:More than 700 Screened for Skin Cancer at 2015 Aspen Ideas Festival 4Health News:Recent Article on Hillary Clinton Plastic Surgery Speculation Illuminates the Reasons Many Professionals Explore Facial Rejuvenation, says Dr. J 2Health News:Recent Article on Hillary Clinton Plastic Surgery Speculation Illuminates the Reasons Many Professionals Explore Facial Rejuvenation, says Dr. J 3Health News:Celestix Now Offers Virtual Editions of Its Unified Remote Access and SSO Platforms to Enable Easy Deployment in Virtualized Environments 2Health News:Celestix Now Offers Virtual Editions of Its Unified Remote Access and SSO Platforms to Enable Easy Deployment in Virtualized Environments 3Health News:Celestix Now Offers Virtual Editions of Its Unified Remote Access and SSO Platforms to Enable Easy Deployment in Virtualized Environments 4Health News:Catalent Biologics Adds New Technology Platform to Enable Antibody Combination Therapies 2Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 2Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 3
... prominent roles in a recent study on the cognitive effects ... and end of one season, 22 percent of those students ... and learning skills than expected, as opposed to only 4 ... shortly after the season and we do not know how ...
... May 17 (HealthDay News) -- Parents of young children with ... bed as their child to monitor their condition, but the ... parents and kids, new research finds. In the study, ... General Hospital for Children in Boston examined the sleeping arrangements ...
... for years that when the proteins RalA and RalB are ... However, until this week, no study had explored the effects ... on the path to developing drugs to target these proteins. ... prostate cancer, to shortened survival in squamous cell carcinoma, a ...
... racial and ethnic disparities in breast cancer exist, they are ... assess the extent of tumors before surgery, according to new ... researchers at the 2012 Annual Meeting of the American Society ... that we didn,t see any differences between black and white ...
... ARBOR, Mich. People with bleeding brain aneurysms have ... they receive aggressive emergency treatment from a specialized team ... patients like them every year, according to new guidelines ... and immediately treating this kind of "bleeding stroke", and ...
... -- A new study confirms the widespread belief that athletes ... may hold clues for managing pain in the general population. ... of more than 550 athletes and more than 330 people ... women, and evaluated pain thresholds (the minimum level of intensity ...
Cached Medicine News:Health News:Parents Often Lose Sleep Over Child's Epilepsy, Study Finds 2Health News:Protein RAL associated with aggressive characteristics in prostate, bladder and skin cancers 2Health News:Fox Chase researchers find no disparities in imaging before breast cancer surgery 2Health News:Specialized care by experienced teams cuts death and disability from bleeding brain aneurysms 2Health News:Specialized care by experienced teams cuts death and disability from bleeding brain aneurysms 3Health News:Athletes Really Do Play Through the Pain 2